- Investing Ideas
- Swedish Pharmaceuticals & Biotech Healthy high growth potential
Swedish Pharmaceuticals & Biotech Healthy high growth potential
Results
6
Analysts expect these companies to experience strong growth in earnings over the next 3 years. They also meet criteria around being in an acceptable financial position.
6 companies
Camurus
Market Cap: SEK 37.1b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMX
SEK 623.50
7D
0.5%
1Y
-12.1%
Bonesupport Holding
Market Cap: SEK 14.1b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BONEX
SEK 214.80
7D
6.3%
1Y
-36.0%
BioArctic
Market Cap: SEK 28.6b
Develops biological drugs for patients with central nervous system disorders in Sweden.
BIOA B
SEK 322.60
7D
5.1%
1Y
53.0%
Genovis AB (publ.)
Market Cap: SEK 1.4b
Develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia.
GENO
SEK 20.25
7D
5.0%
1Y
-27.0%
AlzeCure Pharma
Market Cap: SEK 874.3m
Operates as a pharmaceutical company that develops small-molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system.
ALZCUR
SEK 6.34
7D
0.6%
1Y
105.8%
Moberg Pharma
Market Cap: SEK 460.1m
A pharmaceutical company, develops and commercializes medical products primarily in Sweden.
MOB
SEK 9.79
7D
5.6%
1Y
7.1%